SC 13D/A

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934
(Amendment No. 4)*

Cornerstone Therapeutics Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

21924P103

(CUSIP Number)

David B. Clement
Smith, Anderson, Blount, Dorsett, Mitchell, & Jernigan, LLP
2500 Wachovia Capitol Center
Post Office Box 2611
Raleigh, North Carolina 27602-2611
(919) 821-6754

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

December 16, 2010

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box: o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

TABLE OF CONTENTS

	Item 5. Interest in Securities of the Issuer.
	Item 7. Material to be Filed as Exhibits.
SIGNATURES
EXHIBIT INDEX
EX-10.09
EX-10.11

1.	NAMES OF REPORTING PERSONS Cornerstone Biopharma Holdings, Ltd.
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a)   o
	(b)   o   Joint Filing
3.	SEC USE ONLY
4.	SOURCE OF FUNDS
	OO (See Item 5)
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):
	o
6.	CITIZENSHIP OR PLACE OF ORGANIZATION:
	Anguilla
		7.	SOLE VOTING POWER:
NUMBER OF			0
SHARES		8.	SHARED VOTING POWER:
BENEFICIALLY
OWNED BY			1,567,225 (See Item 5)
EACH		9.	SOLE DISPOSITIVE POWER:
REPORTING
PERSON			0
WITH		10.	SHARED DISPOSITIVE POWER:
			1,567,225 (See Item 5)
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
	1,567,225 (See Item 5)
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES:
	o
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11:
	6.1%(1)
14.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
	HC

(1) Calculated based on 25,643,964 shares of the Issuer’s common stock outstanding as of October 29, 2010 (as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 4, 2010).

1.	NAMES OF REPORTING PERSONS Carolina Pharmaceuticals Ltd.
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a)   o
	(b)   o   Joint Filing
3.	SEC USE ONLY
4.	SOURCE OF FUNDS
	OO (See Item 5)
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):
	o
6.	CITIZENSHIP OR PLACE OF ORGANIZATION:
	Bermuda
		7.	SOLE VOTING POWER:
NUMBER OF			0
SHARES		8.	SHARED VOTING POWER:
BENEFICIALLY
OWNED BY			1,443,913 (See Item 5)
EACH		9.	SOLE DISPOSITIVE POWER:
REPORTING
PERSON			0
WITH		10.	SHARED DISPOSITIVE POWER:
			1,443,913 (See Item 5)
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
	1,443,913 (See Item 5)
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES:
	o
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11:
	5.6%(2)
14.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
	CO

(2) Calculated based on 25,643,964 shares of the Issuer’s common stock outstanding as of October 29, 2010 (as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 4, 2010).

1.	NAMES OF REPORTING PERSONS Carolina Pharmaceuticals Holdings, Ltd.
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a)   o
	(b)   o   Joint Filing
3.	SEC USE ONLY
4.	SOURCE OF FUNDS
	OO (See Item 5)
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):
	o
6.	CITIZENSHIP OR PLACE OF ORGANIZATION:
	Bermuda
		7.	SOLE VOTING POWER:
NUMBER OF			0
SHARES		8.	SHARED VOTING POWER:
BENEFICIALLY
OWNED BY			1,443,913 (See Item 5)
EACH		9.	SOLE DISPOSITIVE POWER:
REPORTING
PERSON			0
WITH		10.	SHARED DISPOSITIVE POWER:
			1,443,913 (See Item 5)
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
	1,443,913 (See Item 5)
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES:
	o
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11:
	5.6%(3)
14.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
	HC

(3) Calculated based on 25,643,964 shares of the Issuer’s common stock outstanding as of October 29, 2010 (as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 4, 2010).

1.	NAMES OF REPORTING PERSONS Craig A. Collard
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a)   o
	(b)   o   Joint Filing
3.	SEC USE ONLY
4.	SOURCE OF FUNDS
	OO (See Item 5)
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):
	o
6.	CITIZENSHIP OR PLACE OF ORGANIZATION:
	United States
		7.	SOLE VOTING POWER:
NUMBER OF			306,531 (See Item 5)
SHARES		8.	SHARED VOTING POWER:
BENEFICIALLY
OWNED BY			3,011,138 (See Item 5)
EACH		9.	SOLE DISPOSITIVE POWER:
REPORTING
PERSON			306,531 (See Item 5)
WITH		10.	SHARED DISPOSITIVE POWER:
			3,011,138 (See Item 5)
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
	3,317,669 (See Item 5)
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES:
	o
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11:
	12.8%(4)
14.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
	IN

(4) Calculated based on Mr. Collard’s 306,531 shares of the Issuer’s common stock underlying options exercisable within 60 days plus 25,643,964 shares of the Issuer’s common stock outstanding as of October 29, 2010 (as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 4, 2010).

Schedule 13D/A

This Amendment No. 4 (this “Amendment”) amends the Report on Schedule 13D, originally filed on May 12, 2008, as previously amended and restated by Amendment No. 1, filed on November 7, 2008, Amendment No. 2, filed on May 18, 2009, and Amendment No. 3, filed on August 4, 2009 (as amended, the “Schedule 13D/A”). Except as provided herein, this Amendment does not modify any of the information previously reported on the Schedule 13D/A. Capitalized terms used and not otherwise defined have the meaning given to them in the Schedule 13D/A.

Item 5. Interest in Securities of the Issuer.

Item 5 is hereby amended and restated as follows:

(a) and (b). As of the date of this Schedule 13D/A:

(i) CBPHLtd has shared power to vote or to direct the vote of, and shared power to dispose or to direct the disposition of, 1,567,225 shares of common stock of the Issuer, which represents approximately 6.1% of the Issuer’s outstanding common stock;

(ii) Carolina has shared power to vote or to direct the vote of, and shared power to dispose or to direct the disposition of, 1,443,913 shares of common stock of the Issuer, which represents approximately 5.6% of the Issuer’s outstanding common stock;

(iii) Carolina Holdings beneficially owns 100% of Carolina, and consequently may be deemed to be the beneficial owner of any shares of common stock beneficially owned by Carolina;

(iv) Craig A. Collard may be deemed to have sole power to vote or to direct the vote of, and sole power to dispose or to direct the disposition of, 306,531 shares of common stock of the Issuer underlying options exercisable within 60 days, which represents approximately 1.2% of the Issuer’s outstanding common stock. Mr. Collard acquired these options pursuant the Cornerstone BioPharma Holdings, Inc. 2005 Stock Incentive Plan and the Cornerstone Therapeutics Inc. 2004 Stock Incentive Plan (the “2004 Plan”). Copies of these plans, as well as the forms of option awards made thereunder, are referenced herein as Exhibits 10.12 through 10.16. Mr. Collard owns 100% of CBPHLtd, and consequently may be deemed to be the beneficial owner of any shares deemed beneficially owned by CBPHLtd. Mr. Collard is the Chief Executive Officer, Chairman of the Board, and a Director of Carolina and Carolina Holdings, and consequently may be deemed to be beneficial owner of any shares deemed beneficially owned by Carolina and Carolina Holdings. Mr. Collard disclaims beneficial ownership of the shares held by CBPHLtd, Carolina, and Carolina Holdings, except to the extent of his pecuniary interest therein.

On July 28, 2009, in connection with the closing of the Initial Stock Sale and pursuant to the terms of the Stockholders Stock Purchase Agreement, CBPHLtd and the Lutz Family Limited Partnership, an entity controlled by Steven M. Lutz, the Issuer’s Executive Vice President, Manufacturing and Trade, sold 1,250,000 and 350,000 shares, respectively, of the Issuer’s common stock to Chiesi at a price of $5.50 per share, for aggregate proceeds of $8.8 million.

In connection with the closing of the Initial Stock Sale on July 28, 2009, options to purchase 145,825 shares of common stock of the Issuer beneficially owned by Mr. Collard became immediately exercisable.

As discussed in Item 3 above, pursuant to the Governance Agreement, Chiesi is permitted to make additional purchases of the Issuer’s common stock to the extent necessary to maintain its beneficial ownership of the Issuer’s common stock at 51% on a Fully Diluted Basis (as defined in the Governance Agreement). As a result of the issuance of additional equity awards under the 2004 Plan following the closing of the Initial Stock Sale, Chiesi’s beneficial ownership on a Fully Diluted Basis had dropped below 51%. Accordingly, Chiesi approached CBPHLtd and the Lutz Family Limited Partnership regarding their willingness to sell additional shares to Chiesi in a private transaction. The parties agreed that a private sale was in the best interests of the parties, the Issuer and the Issuer’s other stockholders in that it would avoid potential short-term market distortions that could have occurred had Chiesi sought to purchase the shares in the open market.

Accordingly, on December 16, 2010, CBPHLtd and the Lutz Family Limited Partnership sold an additional 385,000 and 65,000 shares, respectively, of the Issuer’s common stock to Chiesi pursuant to a stock purchase agreement dated December 16, 2010 (the “December 16, 2010 Stock Purchase Agreement”) at a price of $6.02 per share, for aggregate proceeds of $2.7 million. The agreed-upon sales price was determined based on the average closing price of the Issuer’s common stock during the twenty trading days prior to the date of the sale. The description of the December 16, 2010 Stock Purchase Agreement does not purport to be complete and is qualified in its entirety by the full text of the December 16, 2010 Stock Purchase Agreement, which is referenced herein as Exhibit 10.11.

(c). Except as described herein, none of the Reporting Persons has effected any transaction in the Issuer’s common stock during the past 60 days.

(d) and (e). Not applicable.

Item 7. Material to be Filed as Exhibits.

Item 7 is hereby amended and restated as follows:

Exhibit Number	Description
Exhibit 10.01	Stock Purchase Agreement, dated as of May 6, 2009, by and between Chiesi Farmaceutici SpA and the Issuer (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed on May 12, 2009 (SEC File No. 000-50767)).
Exhibit 10.02	Stock Purchase Agreement, dated as of May 6, 2009, by and among Chiesi Farmaceutici SpA, Cornerstone Biopharma Holdings, Ltd. and Lutz Family Limited Partnership (previously filed with Amendment No. 1 to the Reporting Persons’ Schedule 13D, filed on May 18, 2009 (SEC File No. 005-79887)).
Exhibit 10.03	Governance Agreement, dated as of May 6, 2009, by and among the Issuer, Chiesi Farmaceutici SpA, and solely with respect to the sections identified therein, Cornerstone Biopharma Holdings, Ltd., Carolina Pharmaceuticals Ltd. and Lutz Family Limited Partnership (incorporated by reference to Exhibit 10.3 to the Issuer’s Current Report on Form 8-K filed on May 12, 2009 (SEC File No. 000-50767)).
Exhibit 10.04	Stockholders Agreement, dated as of May 6, 2009, by and among the Issuer, Chiesi Farmaceutici SpA, Craig A. Collard, Steven M. Lutz, Cornerstone Biopharma Holdings, Ltd., Carolina Pharmaceuticals Ltd. and Lutz Family Limited Partnership (incorporated by reference to Exhibit 10.4 to the Issuer’s Current Report on Form 8-K filed on May 12, 2009 (SEC File No. 000-50767)).
Exhibit 10.05	Registration Rights Agreement, dated as of May 6, 2009, by and between the Issuer and Chiesi Farmaceutici SpA (incorporated by reference to Exhibit 10.5 to the Issuer’s Current Report on Form 8-K filed on May 12, 2009 (SEC File No. 000-50767)).
Exhibit 10.06	Registration Rights Agreement, dated as of May 6, 2009, by and among the Issuer, Craig A. Collard, Steven M. Lutz, Cornerstone Biopharma Holdings, Ltd., Carolina Pharmaceuticals Ltd. and Lutz Family Limited Partnership (incorporated by reference to Exhibit 10.6 to the Issuer’s Current Report on Form 8-K filed on May 12, 2009 (SEC File No. 000-50767)).
Exhibit 10.07	Voting Agreement, dated as of May 6, 2009, by and between the Issuer and Chiesi Farmaceutici SpA (incorporated by reference to Exhibit 10.7 to the Issuer’s Current Report on Form 8-K filed on May 12, 2009 (SEC File No. 000-50767)).
Exhibit 10.08	Voting Agreement, dated as of May 6, 2009, by and among Chiesi Farmaceutici SpA, Craig A. Collard, Steven M. Lutz, Cornerstone Biopharma Holdings, Ltd., Carolina Pharmaceuticals Ltd., Lutz Family Limited Partnership, Brian Dickson, M.D., Joshua Franklin, David Price, Alan Roberts and, solely with respect to Section 2(b) thereof, the Issuer (incorporated by reference to Exhibit 10.8 to the Issuer’s Current Report on Form 8-K filed on May 12, 2009 (SEC File No. 000-50767)).
Exhibit 10.09	Joint Filing Agreement, dated as of December 20, 2010, by and among Cornerstone Biopharma Holdings, Ltd., Carolina Pharmaceuticals Ltd., Carolina Pharmaceuticals Holdings, Ltd., and Craig A. Collard.
Exhibit 10.10	Amendment to Stockholders Agreement, dated as of June 26, 2009, by and among the Issuer, Chiesi Farmaceutici SpA, Craig A. Collard, Steven M. Lutz, Cornerstone Biopharma Holdings, Ltd., Carolina Pharmaceuticals Ltd. and Lutz Family Limited Partnership (incorporated by reference to Exhibit 10.2 to the Issuer’s Current Report on Form 8-K filed on June 29, 2009 (SEC File No. 000-50767).
Exhibit 10.11	Stock Purchase Agreement, dated as of December 16, 2010, by and among Chiesi Farmaceutici SpA, Cornerstone Biopharma Holdings, Ltd. and Lutz Family Limited Partnership and, solely with respect to Section 4.1 thereof, the Issuer, Carolina Pharmaceuticals Ltd., Craig A. Collard and Steven M. Lutz.
Exhibit 10.12	Cornerstone BioPharma Holdings, Inc. 2005 Stock Incentive Plan (as Amended and Restated effective October 31, 2008) (incorporated by reference to Exhibit 10.37 to the Issuer’s Current Report on Form 8-K dated October 30, 2008) (SEC File No. 000-50767)).
Exhibit 10.13	Form of Nonstatutory Stock Option Agreement granted under the Cornerstone BioPharma Holdings, Inc. 2005 Stock Incentive Plan (incorporated by reference to Exhibit 10.39 to the Issuer’s Current Report on Form 8-K dated October 30, 2008) (SEC File No. 000-50767)).
Exhibit 10.14	Cornerstone Therapeutics Inc. 2004 Stock Incentive Plan, as Amended and Restated May 20, 2010 (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K dated May 20, 2010 (SEC File No. 000-50767)).

Exhibit Number	Description
Exhibit 10.15	Form of Incentive Stock Option Agreement granted under the 2004 Stock Incentive Plan (incorporated by reference to Exhibit 10.68 to the Issuer’s Annual Report on Form 10-K for the year ended December 31, 2008) (SEC File No. 000-50767)).
Exhibit 10.16	Form of Nonstatutory Stock Option Agreement granted under the 2004 Stock Incentive Plan (incorporated by reference to Exhibit 10.70 to the Issuer’s Annual Report on Form 10-K for the year ended December 31, 2008) (SEC File No. 000-50767)).

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	CORNERSTONE BIOPHARMA HOLDINGS, LTD.
Dated: December 20, 2010
	/s/ Craig A. Collard
	Name:	Craig A. Collard
	Title:	President and Chief Executive Officer
	CAROLINA PHARMACEUTICALS LTD.
	/s/ Craig A. Collard
	Name:	Craig A. Collard
	Title:	President and Chief Executive Officer
	CAROLINA PHARMACEUTICALS HOLDINGS, LTD.
	/s/ Craig A. Collard
	Name:	Craig A. Collard
	Title:	President and Chief Executive Officer
	/s/ Craig A. Collard
	Craig A. Collard

EXHIBIT INDEX

Exhibit Number	Description
Exhibit 10.01	Stock Purchase Agreement, dated as of May 6, 2009, by and between Chiesi Farmaceutici SpA and the Issuer (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed on May 12, 2009 (SEC File No. 000-50767)).
Exhibit 10.02	Stock Purchase Agreement, dated as of May 6, 2009, by and among Chiesi Farmaceutici SpA, Cornerstone Biopharma Holdings, Ltd. and Lutz Family Limited Partnership (previously filed with Amendment No. 1 to the Reporting Persons’ Schedule 13D, filed on May 18, 2009 (SEC File No. 005-79887)).
Exhibit 10.03	Governance Agreement, dated as of May 6, 2009, by and among the Issuer, Chiesi Farmaceutici SpA, and solely with respect to the sections identified therein, Cornerstone Biopharma Holdings, Ltd., Carolina Pharmaceuticals Ltd. and Lutz Family Limited Partnership (incorporated by reference to Exhibit 10.3 to the Issuer’s Current Report on Form 8-K filed on May 12, 2009 (SEC File No. 000-50767)).
Exhibit 10.04	Stockholders Agreement, dated as of May 6, 2009, by and among the Issuer, Chiesi Farmaceutici SpA, Craig A. Collard, Steven M. Lutz, Cornerstone Biopharma Holdings, Ltd., Carolina Pharmaceuticals Ltd. and Lutz Family Limited Partnership (incorporated by reference to Exhibit 10.4 to the Issuer’s Current Report on Form 8-K filed on May 12, 2009 (SEC File No. 000-50767)).
Exhibit 10.05	Registration Rights Agreement, dated as of May 6, 2009, by and between the Issuer and Chiesi Farmaceutici SpA (incorporated by reference to Exhibit 10.5 to the Issuer’s Current Report on Form 8-K filed on May 12, 2009 (SEC File No. 000-50767)).
Exhibit 10.06	Registration Rights Agreement, dated as of May 6, 2009, by and among the Issuer, Craig A. Collard, Steven M. Lutz, Cornerstone Biopharma Holdings, Ltd., Carolina Pharmaceuticals Ltd. and Lutz Family Limited Partnership (incorporated by reference to Exhibit 10.6 to the Issuer’s Current Report on Form 8-K filed on May 12, 2009 (SEC File No. 000-50767)).
Exhibit 10.07	Voting Agreement, dated as of May 6, 2009, by and between the Issuer and Chiesi Farmaceutici SpA (incorporated by reference to Exhibit 10.7 to the Issuer’s Current Report on Form 8-K filed on May 12, 2009 (SEC File No. 000-50767)).
Exhibit 10.08	Voting Agreement, dated as of May 6, 2009, by and among Chiesi Farmaceutici SpA, Craig A. Collard, Steven M. Lutz, Cornerstone Biopharma Holdings, Ltd., Carolina Pharmaceuticals Ltd., Lutz Family Limited Partnership, Brian Dickson, M.D., Joshua Franklin, David Price, Alan Roberts and, solely with respect to Section 2(b) thereof, the Issuer (incorporated by reference to Exhibit 10.8 to the Issuer’s Current Report on Form 8-K filed on May 12, 2009 (SEC File No. 000-50767)).
Exhibit 10.09	Joint Filing Agreement, dated as of December 20, 2010, by and among Cornerstone Biopharma Holdings, Ltd., Carolina Pharmaceuticals Ltd., Carolina Pharmaceuticals Holdings, Ltd., and Craig A. Collard.
Exhibit 10.10	Amendment to Stockholders Agreement, dated as of June 26, 2009, by and among the Issuer, Chiesi Farmaceutici SpA, Craig A. Collard, Steven M. Lutz, Cornerstone Biopharma Holdings, Ltd., Carolina Pharmaceuticals Ltd. and Lutz Family Limited Partnership (incorporated by reference to Exhibit 10.2 to the Issuer’s Current Report on Form 8-K filed on June 29, 2009 (SEC File No. 000-50767).
Exhibit 10.11	Stock Purchase Agreement, dated as of December 16, 2010, by and among Chiesi Farmaceutici SpA, Cornerstone Biopharma Holdings, Ltd. and Lutz Family Limited Partnership and, solely with respect to Section 4.1 thereof, the Issuer, Carolina Pharmaceuticals Ltd., Craig A. Collard and Steven M. Lutz.
Exhibit 10.12	Cornerstone BioPharma Holdings, Inc. 2005 Stock Incentive Plan (as Amended and Restated effective October 31, 2008) (incorporated by reference to Exhibit 10.37 to the Issuer’s Current Report on Form 8-K dated October 30, 2008) (SEC File No. 000-50767)).

Exhibit Number	Description
Exhibit 10.13	Form of Nonstatutory Stock Option Agreement granted under the Cornerstone BioPharma Holdings, Inc. 2005 Stock Incentive Plan (incorporated by reference to Exhibit 10.39 to the Issuer’s Current Report on Form 8-K dated October 30, 2008) (SEC File No. 000-50767)).
Exhibit 10.14	Cornerstone Therapeutics Inc. 2004 Stock Incentive Plan, as Amended and Restated May 20, 2010 (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K dated May 20, 2010 (SEC File No. 000-50767)).
Exhibit 10.15	Form of Incentive Stock Option Agreement granted under the 2004 Stock Incentive Plan (incorporated by reference to Exhibit 10.68 to the Issuer’s Annual Report on Form 10-K for the year ended December 31, 2008) (SEC File No. 000-50767)).
Exhibit 10.16	Form of Nonstatutory Stock Option Agreement granted under the 2004 Stock Incentive Plan (incorporated by reference to Exhibit 10.70 to the Issuer’s Annual Report on Form 10-K for the year ended December 31, 2008) (SEC File No. 000-50767)).

SCHEDULE I

Executive Officers and Directors of Cornerstone Biopharma Holdings, Ltd.

	Position with
	Cornerstone
	Biopharma Holdings,
Name	Ltd.	Principal Occupation	Business Address	Citizenship
Craig A. Collard	President, Chief Executive Officer and Director	President, Chief Executive Officer and Chairman of Cornerstone Therapeutics Inc.	c/o Cornerstone Therapeutics Inc. 1255 Crescent Green Drive Suite 250 Cary, NC 27518	United States

Executive Officers and Directors of Each of
Carolina Pharmaceuticals Ltd. and Carolina Pharmaceuticals Holdings, Ltd.

	Position with each of
	Carolina
	Pharmaceuticals Ltd.
	and Carolina
	Pharmaceuticals
Name	Holdings, Ltd.	Principal Occupation	Business Address	Citizenship
Craig A. Collard	President, Chief Executive Officer and Director	President, Chief Executive Officer and Chairman of Cornerstone Therapeutics Inc.	c/o Cornerstone Therapeutics Inc. 1255 Crescent Green Drive Suite 250 Cary, NC 27518	United States
Steven M. Lutz	Deputy Chairman and Director	Executive Vice President, Manufacturing and Trade of Cornerstone Therapeutics Inc.	c/o Cornerstone Therapeutics Inc. 1255 Crescent Green Drive Suite 250 Cary, NC 27518	United States
Carol Summers	Secretary	Senior Corporate Administrator Appleby Services (Bermuda) Ltd.	Canon’s Court 22 Victoria Street Hamilton HM 12 Bermuda.	Bermuda

EX-10.09

EXHIBIT 10.09

JOINT FILING AGREEMENT

Each of the undersigned hereby agrees and consents that the Schedule 13D/A filed herewith (the “Schedule 13D/A”) by Cornerstone BioPharma Holdings, Ltd. is filed on behalf of each of them pursuant to the authorization of the undersigned to make such filing and that such Schedule 13D/A is filed jointly on behalf of each of them, pursuant to Sections 13(d) and 13(g) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, including Rule 13d-1(k)(1). Each of the undersigned hereby agrees that such Schedule 13D/A is, and any further amendments to the Schedule 13D/A will be, filed on behalf of each of the undersigned. Each of the persons is not responsible for the completeness or accuracy of the information concerning the other persons making this filing unless such person knows or has reason to believe that such information is inaccurate. This agreement may be signed in counterparts. This agreement is effective as of December 20, 2010.

	CORNERSTONE BIOPHARMA HOLDINGS, LTD.
Dated: December 20, 2010
	/s/ Craig A. Collard
	Name:	Craig A. Collard
	Title:	President and Chief Executive Officer
	CAROLINA PHARMACEUTICALS LTD.
	/s/ Craig A. Collard
	Name:	Craig A. Collard
	Title:	President and Chief Executive Officer
	CAROLINA PHARMACEUTICALS HOLDINGS, LTD.
	/s/ Craig A. Collard
	Name:	Craig A. Collard
	Title:	President and Chief Executive Officer
	/s/ Craig A. Collard
	Craig A. Collard

EX-10.11

Exhibit 10.11

STOCK PURCHASE AGREEMENT

by and among

CHIESI FARMACEUTICI SPA,

CORNERSTONE BIOPHARMA HOLDINGS, LTD.,

LUTZ FAMILY LIMITED PARTNERSHIP

and

THE STOCKHOLDERS NAMED HEREIN AND

CORNERSTONE THERAPEUTICS, INC. (solely with respect to Section 4.1)

Dated as of December 16, 2010

TABLE OF CONTENTS

			Page
ARTICLE I PURCHASE AND SALE OF SHARES				1
	Section 1.1.	Purchase and Sale		1
	Section 1.2.	Consideration		1
	Section 1.3.	Closing		1
	Section 1.4.	Closing Deliveries by the Sellers		2
	Section 1.5.	Closing Deliveries by Purchaser		2
ARTICLE II REPRESENTATIONS AND WARRANTIES OF THE SELLERS				2
	Section 2.1.	Ownership of Shares		2
	Section 2.2.	Authority		2
	Section 2.3.	Consents and Approvals; No Violations		2
	Section 2.4.	Disclosure of Information and Investment Experience		3
	Section 2.5.	No Additional Representations		3
ARTICLE III REPRESENTATIONS AND WARRANTIES OF PURCHASER				3
	Section 3.1.	Organization		4
	Section 3.2.	Authority		4
	Section 3.3.	Consents and Approvals; No Violations		4
	Section 3.4.	Financing		4
	Section 3.5.	Brokers and Other Advisors		4
	Section 3.6.	Investment Intent		5
	Section 3.7.	Disclosure of Information and Investment Experience		5
	Section 3.8.	No Additional Representations		5
ARTICLE IV MISCELLANEOUS				5
	Section 4.1.	Stockholders Agreement Waiver		5
	Section 4.2.	Transfer Taxes		6
	Section 4.3.	Fees and Expenses		6
	Section 4.4.	Notices		6
	Section 4.5.	Entire Agreement		7
	Section 4.6.	Waivers		7
	Section 4.7.	No Third-Party Beneficiaries		7
	Section 4.8.	Assignment; Binding Effect		7
	Section 4.9.	GOVERNING LAW		7
	Section 4.10.	CONSENT TO JURISDICTION AND SERVICE OF PROCESS; WAIVER OF JURY TRIAL		8
	Section 4.11.	Remedies		8
	Section 4.12.	Invalid Provisions		8

TABLE OF CONTENTS
(continued)

			Page
	Section 4.13.	Counterparts		9
	Section 4.14.	Interpretation		9
Exhibit A: Sellers’ Holdings

ii

INDEX OF DEFINED TERMS

	Page
affiliate		10
Agreement		1
business day		10
Closing		2
Closing Date		2
Common Stock		1
Company		1
Consideration		1
contract		3
control		10
Encumbrances		2
expenses		6
Governance Agreement		1
Governmental Authority		2
person		10
Purchaser		1
Shares		1
Stockholders Agreement		1

iii

STOCK PURCHASE AGREEMENT

     This STOCK PURCHASE AGREEMENT, dated as of December 16, 2010 (this “Agreement”), is by and among CHIESI FARMACEUTICI SPA, a corporation organized under the laws of Italy (“Purchaser”), CORNERSTONE BIOPHARMA HOLDINGS, LTD., a limited liability company organized under the laws of Anguilla, and LUTZ FAMILY LIMITED PARTNERSHIP, a Nevada limited partnership (collectively, the “Sellers”) and solely with respect to Section 4.1, Cornerstone Therapeutics Inc., a Delaware corporation (the “Company”) and CAROLINA PHARMACEUTICALS, LTD., a limited liability company organized under the laws of Bermuda, Craig A. Collard and Steven M. Lutz (collectively, the “Stockholders”).

RECITALS

     WHEREAS, each Seller is the record and beneficial owner of the number of shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company, set forth opposite such Seller’s name on Exhibit A hereto (collectively, the “Shares”);

     WHEREAS, the Shares of each Seller are not “Covered Shares” as defined in that certain Stockholders Agreement, dated as of May 6, 2009 (the “Stockholders Agreement”), by and among the Company, the Purchaser, the Sellers and the Stockholders;

     WHEREAS, each Seller desires to sell the amount of Shares set forth opposite such Seller’s name on Exhibit A hereto to the Purchaser, and the Purchaser desires to purchase such Shares from the Sellers;

     WHEREAS, pursuant to Section 2.1(a) of that certain Governance Agreement, dated as of May 6, 2009 (the “Governance Agreement”), by and among the Company, the Purchaser, the Sellers and the other stockholders named therein, the Purchaser may acquire additional Common Stock to the extent necessary to maintain Beneficial Ownership (as defined in the Governance Agreement) at an amount equal to 51% of Common Stock on a Fully Diluted Basis (as defined in the Governance Agreement); and

     WHEREAS, pursuant to Section 5.4 of the Stockholders Agreement, the Company, the Purchaser, each of the Sellers (with respect to the Shares being sold by the other Seller), and each of the Stockholders are hereby waiving the provisions of Section 3.2(b) thereof with respect to transfer of the Shares.

     NOW, THEREFORE, the parties hereby agree as follows:

ARTICLE I

PURCHASE AND SALE OF SHARES

     Section 1.1. Purchase and Sale. At the Closing, upon the terms and subject to the conditions set forth in this Agreement, each Seller will sell, assign, transfer and deliver the amount of Shares set forth opposite such Seller’s name on Exhibit A hereto to the Purchaser, and the Purchaser will purchase and accept such Shares from the Sellers.

     Section 1.2. Consideration. The consideration (the “Consideration”) to be paid to the Sellers for the Shares at the Closing shall be U.S. $6.02 per share in cash.

     Section 1.3. Closing. The consummation of the transactions contemplated hereby shall take place at a closing (the “Closing”) to be held at the offices of Morgan, Lewis & Bockius LLP, 101 Park Avenue, New York, New York 10178, or by electronic transmission on terms agreed upon by the Purchaser and the Sellers, simultaneously with the execution and delivery of this Agreement. The date of the Closing is referred to herein as the “Closing Date”. The Closing shall be deemed to occur as of 12:01 a.m. Eastern Standard Time on the Closing Date.

     Section 1.4. Post Closing Deliveries by the Sellers. As soon as reasonably practicable after the Closing, but no later than five (5) business days, each Seller shall deliver or cause to be delivered to Purchaser a certificate or certificates representing the number of Shares to be sold by it (as set forth on Exhibit A), in each case endorsed in blank or with an executed blank stock power attached and with all transfer tax stamps attached or provided for sufficient to vest good and valid title to the Shares in Purchaser.

     Section 1.5. Closing Deliveries by Purchaser. At the Closing, Purchaser shall deliver the Consideration to the Sellers by wire transfer of immediately available funds in United States dollars to such account or accounts as the Sellers may direct by written notice to Purchaser.

ARTICLE II

REPRESENTATIONS AND WARRANTIES OF THE SELLERS

     Each Seller represents and warrants, severally but not jointly and solely with respect to such Seller and not with respect to the other Seller, to Purchaser as follows:

     Section 2.1. Ownership of Shares. Such Seller is the lawful record and beneficial owner of the number of Shares set forth next to such Seller’s name on Exhibit A free and clear of all liens, charges, security interests, mortgages, pledges, options, preemptive rights, rights of first refusal or first offer, proxies, levies, voting trusts or agreements, or other adverse claims or restrictions on title or transfer of any nature whatsoever (collectively, “Encumbrances”), other than restrictions on transfer imposed under applicable securities laws. Upon the conveyance by such Seller of such Shares and receipt of payment in the manner contemplated by Article I, such Seller will transfer, assign, convey and deliver beneficial and legal title to Purchaser free and clear of all Encumbrances, other than Encumbrances imposed under applicable securities laws or resulting from acts or omissions of Purchaser. The Shares are not “Covered Shares”, as defined in the Stockholders Agreement.

     Section 2.2. Authority. Such Seller is an entity with the requisite partnership or limited liability company power and authority to execute and deliver this Agreement and to perform the transactions contemplated by this Agreement. This Agreement has been duly and validly executed and delivered by such Seller and, assuming the due authorization, execution and delivery of this Agreement by each other party hereto, constitutes legal, valid and binding obligations of such Seller, enforceable against such Seller in accordance with its terms.

     Section 2.3. Consents and Approvals; No Violations.

     (a) The execution, delivery and performance by such Seller of this Agreement and the consummation by such Seller of the transactions contemplated hereby do not and will not require any filing or registration with, notification to, or authorization, permit, consent or approval of, or other action by or in respect of, any U.S. or non-U.S. government, regulatory or administrative authority, agency, instrumentality or commission or any court, tribunal, judicial or arbitral body or other similar authority (a

2

“Governmental Authority”) other than (i) compliance with any applicable requirements of the Securities Exchange Act of 1934, as amended, and (ii) where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not reasonably be expected to prevent or materially delay the consummation of the transactions contemplated hereby.

     (b) The execution, delivery and performance by such Seller of this Agreement and the consummation by such Seller of the transactions contemplated hereby do not and will not (i) result in a violation or breach of, or constitute (with or without notice or lapse of time or both) a default under, or give rise to any right of termination, amendment, cancellation, acceleration or loss of benefits or the creation or acceleration of any right or obligation under or result in the creation of any Encumbrance upon any of the properties or assets of such Seller under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture, deed of trust, loan, credit agreement, lease, license, permit, concession, franchise, purchase order, sales order, contract, agreement or other instrument, understanding or obligation, whether written or oral (a “contract”), to which such Seller is a party or by which any of its properties or assets may be bound or (ii) violate any law applicable to such Seller or any of its properties or assets, except, in each case, for violations, breaches or defaults that would not reasonably be expected to prevent or delay the consummation of the transactions contemplated hereby.

     Section 2.4. Disclosure of Information and Investment Experience.

     (a) Each Seller understands that the transactions contemplated by this Agreement involve substantial risk. Such Seller (i) is a sophisticated investor with respect to the transactions contemplated by this Agreement, (ii) has adequate information concerning the business and financial affairs of the Company to make an informed decision regarding the sale of the Shares pursuant to the terms and conditions of this Agreement, (iii) has independently and without reliance upon the Purchaser, and based on such information as such Seller has deemed appropriate, made its own analysis and decision to sell the Shares to the Purchaser and (iv) has a preexisting business relationship with the Company of a nature and duration that enables such Seller to assess the merits and risks of the transactions contemplated by this Agreement.

     (b) The Purchaser has not given such Seller any investment advice, credit information or opinion on whether the sale of the Shares is prudent.

     (c) Notwithstanding anything to the contrary contained herein, such Seller acknowledges that (i) the Purchaser currently may or may not have, and later may or may not come into possession of, information about the Shares or the Company that is not known to such Seller and that may or may not be material to a decision to sell the Shares; (ii) it has determined to sell the Shares to the Purchaser notwithstanding its lack of such knowledge and (iii) the Purchaser shall not have any liability to any Seller with respect to material information that the Purchaser possesses and/or such Seller’s lack of such information. Each Seller hereby waives and releases any claims relating to the transactions contemplated by this Agreement that it might have against the Purchaser, its subsidiaries or other affiliates, and all of its and their respective officers, directors, employees, shareholders and agents, whether under applicable securities laws or otherwise.

     Section 2.5. No Additional Representations. Except as otherwise expressly set forth in this Article II, such Seller does not make any representation or warranty of any kind, express or implied, in connection with the transactions contemplated by this Agreement. Without limiting the generality of the foregoing, except as expressly set forth in this Article II, no representation or warranty is made by such Seller as to any information provided in any management presentation, through any virtual or physical

3

data room or otherwise, including in respect of any financial projections, estimates, forecasts or other data.

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF PURCHASER

     Purchaser represents and warrants to the Sellers as follows:

     Section 3.1. Organization. Purchaser is a corporation duly organized, validly existing and in good standing (to the extent such concept exists in the relevant jurisdiction) under the laws of the jurisdiction of its organization and has all requisite corporate power and authority to own, license, use, lease and operate its assets and properties and to carry on its business as now being conducted, except where the failure to be so organized, existing and in good standing or to have such power and authority would not reasonably be expected to prevent or delay the consummation of the transactions contemplated hereby.

     Section 3.2. Authority. Purchaser has all requisite corporate power and authority to execute and deliver this Agreement and to perform and consummate the transactions contemplated hereby. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary organization action on the part of Purchaser and no other organizational proceedings on the part of Purchaser are necessary to authorize this Agreement or to consummate such transactions. No vote of the stockholders of Purchaser is required to approve this Agreement or the transactions contemplated hereby. This Agreement has been duly executed and delivered by Purchaser and, assuming the due authorization, execution and delivery of this Agreement by each other party hereto, constitutes a valid and binding obligation of Purchaser enforceable against it in accordance with its terms.

     Section 3.3. Consents and Approvals; No Violations.

     (a) The execution, delivery and performance by Purchaser of this Agreement and the consummation by Purchaser of the transactions contemplated hereby do not and will not require any filing or registration with, notification to, or authorization, permit, consent or approval of, or other action by or in respect of, any Governmental Authority other than (i) compliance with any applicable requirements of the Securities Exchange Act of 1934, as amended, and (ii) where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not reasonably be expected to prevent or materially delay the consummation of the transactions contemplated hereby.

     (b) The execution, delivery and performance by Purchaser of this Agreement and the consummation by Purchaser of the transactions contemplated hereby do not and will not (i) conflict with or result in any breach of any provision of the organizational documents of Purchaser, (ii) result in a violation or breach of, or constitute (with or without notice or lapse of time or both) a default under, or give rise to any right of termination, amendment, cancellation, acceleration or loss of benefits under, or result in the creation of any Encumbrance upon any of the properties or assets of Purchaser or any of its subsidiaries under, any of the terms, conditions or provisions of contract to which Purchaser is a party or any of its subsidiaries is a party or by which any of its properties or assets may be bound or (iii) violate any judgment, order, writ, preliminary or permanent injunction or decree or any statute, law, ordinance, rule or regulation of any Governmental Authority applicable to Purchaser, any of its subsidiaries or any of their properties or assets, except in the case of clauses (ii) or (iii) for violations, breaches or defaults that

4

would not reasonably be expected to prevent or materially delay the consummation of the transactions contemplated hereby.

     Section 3.4. Financing. Purchaser has funds sufficient to pay the Consideration at the Closing.

     Section 3.5. Brokers and Other Advisors. No broker, investment banker, financial advisor or other person is entitled to any broker’s, finder’s, financial advisor’s or other similar fee or commission in connection with the transactions contemplated by this Agreement as a result of any action taken by or on behalf of Purchaser.

     Section 3.6. Investment Intent. Purchaser is acquiring the Shares for its own account, for the purpose of investment only and not with a view to, or for sale in connection with, any distribution thereof in violation of applicable securities laws.

     Section 3.7. Disclosure of Information and Investment Experience.

     (a) The Purchaser understands that the transactions contemplated by this Agreement involve substantial risk. The Purchaser (i) is a sophisticated investor with respect to the transactions contemplated by this Agreement, (ii) has adequate information concerning the business and financial affairs of the Company to make an informed decision regarding the purchase of the Shares pursuant to the terms and conditions of this Agreement, (iii) has independently and without reliance upon either Seller, and based on such information as the Purchaser has deemed appropriate, made its own analysis and decision to purchase the Shares from the Sellers and (iv) has a preexisting business relationship with the Company of a nature and duration that enables the Purchaser to assess the merits and risks of the transactions contemplated by this Agreement.

     (b) Neither Seller has given the Purchaser any investment advice, credit information or opinion on whether the purchase of the Shares is prudent.

     (c) Notwithstanding anything to the contrary contained herein, the Purchaser acknowledges that (i) either Seller currently may or may not have, and later may or may not come into possession of, information about the Shares or the Company that is not known to the Purchaser and that may or may not be material to a decision to purchase the Shares; (ii) it has determined to purchase the Shares from the Sellers notwithstanding its lack of such knowledge and (iii) neither Seller shall have any liability to the Purchaser with respect to material information that such Seller possesses and/or the Purchaser’s lack of such information. The Purchaser hereby waives and releases any claims relating to the transactions contemplated by this Agreement that it might have against either Seller or any of their respective subsidiaries or other affiliates, and all of its and their respective officers, directors, employees, shareholders and agents, whether under applicable securities laws or otherwise.

     Section 3.8. No Additional Representations. Except as otherwise expressly set forth in this Article III, Purchaser does not make any representation or warranty of any kind, express or implied, in connection with the transactions contemplated by this Agreement. Without limiting the generality of the foregoing, except as expressly set forth in this Article III, no representation or warranty is made by Purchaser as to any information provided in any management presentation, through any virtual or physical data room or otherwise, including in respect of any financial projections, estimates, forecasts or other data.

5

ARTICLE IV

MISCELLANEOUS

     Section 4.1. Stockholders Agreement Waiver. Pursuant to Section 5.4 of the Stockholders Agreement, the Company, the Purchaser, each of the Sellers (with respect to the Shares being sold by the other Seller), and the Stockholders hereby waive the application of Section 3.2(b) of the Stockholders Agreement to the transactions contemplated hereby.

     Section 4.2. Transfer Taxes. The responsibility for, and the payment obligation in connection therewith, all transfer, registration, stamp, documentary, sales, use and similar taxes (excluding all applicable gains taxes), and any penalties, interest and additions to such taxes incurred, levied or payable in connection with the transactions contemplated by this Agreement shall be borne and paid by Purchaser and Purchaser will at it own expense file or otherwise submit all necessary returns and other documentation with respect to all such taxes and fees.

     Section 4.3. Fees and Expenses. Except as otherwise provided in this Agreement, each party shall bear its own expenses in connection with the transactions contemplated by this Agreement. For purposes of this Section, “expenses” means the out-of-pocket fees and expenses of any advisors, counsel and accountants, incurred by the party or on its behalf in connection with this Agreement and the transactions contemplated hereby.

     Section 4.4. Notices.

     (a) All notices and other communications under this Agreement must be in writing and delivered to the applicable party or parties in person or by delivery to the address or facsimile number specified below (or to such other address or facsimile number as the recipient previously shall have specified by notice to the other parties hereunder):

If to Sellers:

c/o Cornerstone Therapeutics Inc.
1255 Crescent Green Drive, Suite 250
Cary, NC 27518
Attention: Chief Financial Officer
                 General Counsel
Facsimile: (888) 443-3092

With a copy (which shall not constitute notice) to:

Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.
150 Fayetteville Street, Suite 2500
Raleigh, NC 27601
Attention: David B. Clement
Facsimile: (919) 821-6800

6

If to Purchaser:

Chiesi Farmaceutici SpA
Via Palermo 26/A
43122 Parma, Italy
Attention: President and CEO
                 Corporate Development Director and Legal and Corporate Affairs Director
Facsimile: +39-0521-774468

With copies (which shall not constitute notice) to:

Morgan, Lewis & Bockius LLP
1111 Pennsylvania Avenue, NW
Washington, DC 20004
Attention: Stephen Paul Mahinka
Facsimile: (202) 739-3001

and

Morgan, Lewis & Bockius LLP
101 Park Avenue
New York, New York 10178
Attention: Emilio Ragosa and Steven A. Navarro
Facsimile: (212) 309-6001

     (b) All notices and other communications sent to the applicable address or facsimile number specified above shall be deemed to have been delivered at the earlier of (i) the time of actual receipt by the addressee; (ii) if the notice is sent by facsimile transmission, the time indicated on the transmitting party’s receipt of confirmation of transmission that time is during the addressee’s regular business hours on a business day, and otherwise at 9:00 a.m. on the next business day after such time; and (iii) if the notice is sent by a nationally recognized, reputable overnight courier service, the time shown on the confirmation of delivery provided by that service if that time is during the recipient’s regular business hours on a business day, and otherwise at 9:00 a.m. on the next business day after such time.

     Section 4.5. Entire Agreement. This Agreement and the exhibits, annexes and schedules hereto, constitute the sole and entire agreement among the parties to this Agreement with respect to the subject matter of this Agreement, and supersede all prior and contemporaneous representations, agreements and understandings, written or oral, with respect to the subject matter hereof.

     Section 4.6. Waivers. Subject to applicable law and except as otherwise provided in this Agreement, any party to this Agreement may, at any time prior to the Closing, extend the time for performance of any obligation under this Agreement of any other party or waive compliance with any term or condition of this Agreement by any other party. No such extension or waiver shall be effective unless set forth in a written instrument duly executed by the party granting such extension or waiver. No delay in asserting or exercising a right under this Agreement shall be deemed a waiver of that right.

     Section 4.7. No Third-Party Beneficiaries. The terms and provisions of this Agreement are intended solely for the benefit of each party hereto and their respective successors or permitted assigns, and it is not the intention of the parties to confer third-party beneficiary rights upon any other person.

7

     Section 4.8. Assignment; Binding Effect. Neither this Agreement nor any right, interest or obligation under this Agreement may be assigned by any party to this Agreement, by operation of law or otherwise, without the prior written consent of the other parties to this Agreement and any attempt to do so will be void. Subject to the foregoing, this Agreement is binding upon, inures to the benefit of and is enforceable by the parties to this Agreement and their respective successors and assigns.

     Section 4.9. GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD FOR ANY OF THE CONFLICTS OF LAWS PRINCIPLES THEREOF THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION.

     Section 4.10. CONSENT TO JURISDICTION AND SERVICE OF PROCESS; WAIVER OF JURY TRIAL. EACH PARTY TO THIS AGREEMENT HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE DELAWARE CHANCERY COURT SITTING IN THE COUNTY OF NEW CASTLE, OR IF SUCH COURT SHALL NOT HAVE PROPER JURISDICTION, OF THE UNITED STATES FEDERAL DISTRICT COURT SITTING IN DELAWARE, AND ANY APPELLATE COURT THEREOF, IN RESPECT OF ANY ACTION, SUIT OR PROCEEDING ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, AND AGREES THAT ANY SUCH ACTION, SUIT OR PROCEEDING SHALL BE BROUGHT ONLY IN SUCH COURTS (AND WAIVES AND AGREES NOT TO ASSERT ANY OBJECTION BASED ON FORUM NON CONVENIENS OR ANY OTHER OBJECTION TO VENUE THEREIN OR JURISDICTION THEREOF); PROVIDED, HOWEVER, THAT SUCH CONSENT TO JURISDICTION IS SOLELY FOR THE PURPOSE REFERRED TO IN THIS SECTION 4.10 AND SHALL NOT BE DEEMED TO BE A GENERAL SUBMISSION TO THE JURISDICTION OF SAID COURTS OR IN THE STATE OF DELAWARE OTHER THAN FOR SUCH PURPOSE. Any and all process may be served in any action, suit or proceeding arising in connection with this Agreement by complying with the provisions of Section 4.4. Such service of process shall have the same effect as if the party being served were a resident in the State of Delaware and had been lawfully served with such process in such jurisdiction. The parties hereby waive all claims of error by reason of such service. Nothing herein shall affect the right of any party to serve process in any other manner permitted by law or to commence legal proceedings or otherwise proceed against the other in any other jurisdiction to enforce judgments or rulings of the aforementioned courts. EACH PARTY TO THIS AGREEMENT HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH OF THE PARTIES HERETO (A) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 4.10.

     Section 4.11. Remedies. The parties hereto agree that if any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached, irreparable damage would occur, no adequate remedy at law would exist and damages would be difficult to determine, and that the parties shall be entitled to injunctive relief to prevent breaches of this Agreement and to specific performance of the terms hereof, in addition to any other remedy at law or equity to which the parties may be entitled. Except as otherwise provided herein, all remedies available

8

under this Agreement, at law or otherwise, shall be deemed cumulative and not alternative or exclusive of other remedies. The exercise by any party of a particular remedy shall not preclude the exercise of any other remedy.

     Section 4.12. Invalid Provisions. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future law, (a) such provision will be fully severable, (b) this Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement will remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid or unenforceable provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and the parties hereto shall cooperate in good faith to formulate and implement such provision.

     Section 4.13. Counterparts. This Agreement may be executed in any number of counterparts, all of which will constitute one and the same instrument, and will become effective when a counterpart shall have been executed and delivered by each party to the other parties (except that parties that are affiliates need not deliver counterparts to each other in order for this Agreement to be effective). The exchange of copies of this Agreement or amendments thereto and of signature pages by facsimile transmission or by email transmission in portable document format, or similar format, shall constitute effective execution and delivery of such instrument(s) as to the parties and may be used in lieu of the original Agreement or amendment for all purposes. Signatures of the parties transmitted by facsimile or by email transmission in portable document format, or similar format, shall be deemed to be original signatures for all purposes.

     Section 4.14. Interpretation.

     (a) When a reference is made in this Agreement to an Article or a Section hereof, such reference shall be to an Article or a Section of this Agreement unless otherwise indicated.

     (b) The table of contents and headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

     (c) The parties have participated jointly in negotiating and drafting this Agreement. If an ambiguity or a question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.

     (d) The words “include,” “includes” or “including” shall be deemed to be followed by the words “without limitation.”

     (e) The words “hereof,” “herein” and “hereunder” and words of similar import, when used in this Agreement, refer to this Agreement as a whole and not to any particular provision of this Agreement.

     (f) All terms defined in this Agreement have their defined meanings when used in any certificate or other document made or delivered pursuant hereto, unless otherwise defined therein.

     (g) The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms.

9

     (h) If any action is to be taken by any party hereto pursuant to this Agreement on a day that is not a business day, such action shall be taken on the next business day following such day.

     (i) References to a person are also to its permitted successors and assigns.

     (j) The use of “or” is not intended to be exclusive unless expressly indicated otherwise.

     (k) The term “person” means any natural person, corporation, general partnership, limited partnership, limited or unlimited liability company, proprietorship, joint venture, other business organization, trust, union, association or Governmental Authority.

     (l) Except as otherwise may be provided herein, the term “business day” means any day other than a Saturday, Sunday or day when commercial banks in New York City are permitted or required by law to be closed for the conduct of regular banking business.

     (m) The term “affiliate” means, with respect to any person, any other person that directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with the person specified. The term “control” (including the terms “controlling,” “controlled by” and “under common control with”) means possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, by contract or otherwise.

[signature page follows]

10

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

CHIESI FARMACEUTICI SPA
By:	/s/ Alberto Chiesi
	Name:	Alberto Chiesi
	Title:	President and CEO
CORNERSTONE BIOPHARMA HOLDINGS, LTD.
By:	/s/ Craig A. Collard
	Name:	Craig A. Collard
	Title:	Director
LUTZ FAMILY LIMITED PARTNERSHIP By: STEVEN M. LUTZ, its general partner
/s/ Steven M. Lutz
Steven M. Lutz
CORNERSTONE THERAPEUTICS, INC.
By:	/s/ Andrew K. W. Powell
	Name:	Andrew K. W. Powell
	Title:	Executive Vice President, General Counsel and Secretary
CAROLINA PHARMACEUTICALS, LTD.
By:	/s/ Craig A. Collard
	Name:	Craig A. Collard
	Title:	Director
/s/ Craig A. Collard
Craig A. Collard
/s/ Steven M. Lutz
Steven M. Lutz

Signature Page to Stock Purchase Agreement

EXHIBIT A

SELLERS’ HOLDINGS

Stockholder	No. of Shares to be Sold
CORNERSTONE BIOPHARMA HOLDINGS, LTD.	385,000 shares
LUTZ FAMILY LIMITED PARTNERSHIP	65,000 shares
TOTAL	450,000 shares